FDA user fee hearing
Executive Summary
Rep. Waxman's (D-Calif.) Energy & Commerce/health subcommittee hearing on FDA user fees is tentatively scheduled for Aug. 10. FDA Commissioner Kessler has been scrambling to build a consensus on user fee legislation and recently stepped up agency dialog with PMA and key congressional staffers in a series of meetings in July ("The Pink Sheet" July 20, T&G-8). On July 29, Kessler and CDER Director Carl Peck met with Waxman staffer Bill Schultz for the second time in three weeks. House and Senate staffers are hoping to craft a bill that can win PMA support before the end of the current session of Congress....
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth